LONDON, ONTARIO January 2, 2018 — Dr. Larry Mahan attended BioTech Showcase 2018 during JP Morgan week in San Francisco on behalf of OB Pharmaceuticals for 3 days of business partnering and a corporate presentation on the remarkable preclinical progress of the company’s program on the development of oxynytones, novel molecules showing promise for the treatment and prevention of epilepsy and other related seizure disorders. More than twenty meetings transpired spanning business partnering and potential venture investment.
About BioTech Showcase
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its tenth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.
About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.